SCHEMBL3390342

SCHEMBL3390342

COc1ccc(/C=C/c2cc(O)cc(/C=C/c3ccc(OC)c(O)c3)c2)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 1.00
TUBB1 Q9H4B7 10/20 0.77
TUBB4A P04350 3/20 0.75
TUBB P07437 3/20 0.75
TUBA3C P0DPH7 3/20 0.75
TUBA1B P68363 3/20 0.75
TUBA4A P68366 3/20 0.75
TUBB4B P68371 3/20 0.75
TUBB3 Q13509 3/20 0.75
TUBB2A Q13885 3/20 0.75
TUBB8 Q3ZCM7 3/20 0.75
TUBA3E Q6PEY2 3/20 0.75
TUBA1A Q71U36 3/20 0.75
TUBA1C Q9BQE3 3/20 0.75
TUBB6 Q9BUF5 3/20 0.75
TUBB2B Q9BVA1 3/20 0.75
ALOX5 P09917 2/20 0.75
NQO1 P15559 1/20 0.75
NQO2 P16083 1/20 0.75
SLC22A2 O15244 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30940360 0.96 APP (0.93) APPTUBB1TUBB4ATUBBTUBA3C
SCHEMBL30502377 0.96 APP (0.93) APPTUBB1TUBB4ATUBBTUBA3C
SCHEMBL1486818 0.96 APP (0.93) APPTUBB1TUBB4ATUBBTUBA3C
SCHEMBL31271176 0.96 APP (0.93) APPTUBB1TUBB4ATUBBTUBA3C
SCHEMBL1486816 0.96 APP (0.93) APPTUBB1TUBB4ATUBBTUBA3C
SCHEMBL28445854 0.90 ALOX5 (0.88) APPTUBB1TUBB4ATUBBTUBA3C
SCHEMBL28444241 0.90 ALOX5 (0.88) APPTUBB1TUBB4ATUBBTUBA3C
SCHEMBL22014230 0.90 APP (0.81) APPTUBB1TUBB4ATUBBTUBA3C
SCHEMBL3393305 0.89 TUBB1 (0.83) APPTUBB1TUBB4ATUBBTUBA3C
SCHEMBL22014225 0.89 APP (0.79) APPTUBB1TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190803-A1 BIS(STYRYL)PYRIMIDINE OR BIS(STYRYL)BENZENE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES FEATURING AMYLOIDS COMPRISING THE SAME AS AN ACTIVE INGREDIENT KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-07-29 US claimed
US-20190218181-A1 PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS BASF PERSONAL CARE AND NUTRITION GMBH (DE) 2019-07-18 US disclosed
US-20190218181-A1 PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS BASF PERSONAL CARE AND NUTRITION GMBH (DE) 2019-07-18 US disclosed
WO-2017194590-A1 PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS BASF SE (DE) 2017-11-16 WO disclosed
US-8410116-B2 Bis(styryl)pyrimidine or bis(styryl)benzene compounds, pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for prevention or treatment of diseases featuring amyloids comprising the same as an active ingredient KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-04-02 US disclosed
US-8410116-B2 Bis(styryl)pyrimidine or bis(styryl)benzene compounds, pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for prevention or treatment of diseases featuring amyloids comprising the same as an active ingredient KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-04-02 US disclosed
US-8410116-B2 Bis(styryl)pyrimidine or bis(styryl)benzene compounds, pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for prevention or treatment of diseases featuring amyloids comprising the same as an active ingredient KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-04-02 US disclosed
US-20100190803-A1 BIS(STYRYL)PYRIMIDINE OR BIS(STYRYL)BENZENE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES FEATURING AMYLOIDS COMPRISING THE SAME AS AN ACTIVE INGREDIENT KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-07-29 US disclosed
US-20100190803-A1 BIS(STYRYL)PYRIMIDINE OR BIS(STYRYL)BENZENE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES FEATURING AMYLOIDS COMPRISING THE SAME AS AN ACTIVE INGREDIENT KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-07-29 US disclosed
US-20100190803-A1 BIS(STYRYL)PYRIMIDINE OR BIS(STYRYL)BENZENE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES FEATURING AMYLOIDS COMPRISING THE SAME AS AN ACTIVE INGREDIENT KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218181-A1 PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS HPD, HAAO, PAH APP 257/4885TUBB1 2245/4885TUBB4A 1276/4885
US-20100190803-A1 BIS(STYRYL)PYRIMIDINE OR BIS(STYRYL)BENZENE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES FEATURING AMYLOIDS COMPRISING THE SAME AS AN ACTIVE INGREDIENT PSEN1, APP, BACE1 APP 2/4885TUBB1 461/4885TUBB4A 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.